Syfovre Injection Dosage
Generic name: Pegcetacoplan 15mg in 0.1mL
Dosage form: injection, solution
Drug class: Miscellaneous ophthalmic agents
Medically reviewed by Drugs.com. Last updated on Aug 19, 2024.
Recommended Dosage
The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.
Preparation for Administration
Store SYFOVRE in the refrigerator between 2°C to 8°C (36°F to 46°F); Keep the vial in the original carton to protect from light. | |
Remove the carton from the refrigerator. Keep the vial in the original carton at room temperature 20°C to 25°C (68°F to 77°F), for at least 15 minutes prior to injection, but no longer than 8 hours. Fill the syringe immediately prior to the injection. | |
Do not shake the vial. The vial is for use in a single eye. |
|
Inspect the solution. It is a clear, colorless to light yellow aqueous solution. Do not use if:
|
STEP 1 Gather the supplies needed: |
|||
|
|||
Use aseptic technique to carry out the following preparation steps: | |||
STEP 2 Remove the flip-off cap from the vial (see Figure 1a) and clean the vial septum with an alcohol swab and wait for the alcohol to dry out (see Figure 1b). |
|||
STEP 3 Attach the 5-micron filter needle onto a 1-mL Luer-lock syringe (see Figure 2) by twisting it onto the Luer-lock syringe tip. |
|||
STEP 4 Push the filter needle into the center of the vial septum until the needle is submerged in the drug product to prevent withdrawal of air (see Figure 3a). To withdraw the entire contents of the vial into the syringe, hold the vial at a slightly inclined position. Withdraw the drug product slowly to prevent air bubbles. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid until all of the fluid is withdrawn from the vial (see Figure 3b). *Do not tap the syringe to remove air bubbles. While maintaining the filter needle within the vial, invert the syringe and move the plunger down and up until bubbles move to the top (see Figure 3c). |
|||
STEP 5 Using aseptic technique, disconnect the filter needle from the syringe and dispose of it. Do not use the filter needle for injection. |
|||
STEP 6 Aseptically and firmly attach the injection needle onto the 1-mL Luer-lock syringe (see Figure 4). |
|||
STEP 7 Check for air bubbles by holding the syringe with the needle pointing up. *Do not tap the syringe to remove air bubbles. If there are any air bubbles, remove the needle cap and with the needle end facing up gently advance the plunger to the 0.1 mL dose mark (see Figure 5). Only 0.1 mL (15 mg of SYFOVRE) should be administered to deliver a single dose. Any excess volume should be disposed. The syringe is ready for injection. |
|||
Injection Procedure
Only 0.1 mL (15 mg of SYFOVRE) should be administered to deliver a single dose. Any excess volume should be disposed. Ensure that the injection is given immediately after the preparation of the dose.
Prior to the intravitreal injection, patients should be monitored for elevated intraocular pressure (IOP) using tonometry. If necessary, ocular hypotensive medication can be given to lower the IOP. The intravitreal injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid, and ocular surface should be administered prior to the injection.
Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.1 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.
Immediately following the intravitreal injection, patients should be monitored for elevations in IOP. Additional evaluation may include checking for perfusion of the optic nerve head and tonometry.
Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay.
Each vial should only be used for the treatment of a single eye. If the fellow eye requires treatment, a new sterile, vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before SYFOVRE administration. Repeat same procedure steps as above.
Any unused medicinal product or waste material should be disposed of in accordance with local regulations.
Frequently asked questions
- How do Izervay and Syfovre compare?
- Is Syfovre covered by Medicare?
- How effective is Syfovre for macular degeneration?
More about Syfovre (pegcetacoplan ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
- Breastfeeding
- En español
Patient resources
Professional resources
- Syfovre Injection prescribing information
- Pegcetacoplan (Geographic Atrophy) (Local) (AHFS Monograph)
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.